School of Life and Medical Science, University of Hertfordshire, Hatfield, United Kingdom; Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy.
Gen Hosp Psychiatry. 2013 Sep-Oct;35(5):571-3. doi: 10.1016/j.genhosppsych.2013.04.013. Epub 2013 May 23.
Tropicamide is an antimuscarinic drug usually prescribed as an ophthalmic solution to induce short-term mydriasis and cycloplegia. Over the last 2 years, tropicamide has been reported in both Russia and Italy to be self-administered intravenously (IV) for recreational purposes.
The literature on tropicamide was searched in PsycInfo and Pubmed databases. Considering the absence of peer-reviewed data, results were integrated with a multilingual qualitative assessment of a range of Web sites, drug fora and other online resources (i.e., e-newsgroups, chat rooms, mailing lists, e-newsletters and bulletin boards): between January 2012 and January 2013, exploratory qualitative searches of more than 100 Web sites have been carried out in English and Italian using generic and specific keywords such as "legal highs," "research chemicals," "online pharmacy," "tropicamide," "mydriacil," "tropicacyl," "visumidriatic," "online pharmacies" and "tropicamide recreational abuse" in the Google search engine.
Misuse of tropicamide typically occurs through IV injection; its effects last from 30 min to 6 h, and it is often taken in combination with other psychoactive compounds, most typically alcohol, marijuana and opiates. Medical effects of tropicamide misuse include slurred speech, persistent mydriasis, unconsciousness/unresponsiveness, hallucinations, kidney pain, dysphoria, "open eye dreams," hyperthermia, tremors, suicidal feelings, convulsions, psychomotor agitation, tachycardia and headache.
DISCUSSION/CONCLUSIONS: More large-scale studies need to be carried out to confirm and better describe the extent of tropicamide misuse in the European Union and elsewhere. Health and other professionals should be rapidly informed about this new and alerting trend of misuse.
托吡卡胺是一种抗毒蕈碱药物,通常作为眼科溶液开处方,以诱导短期散瞳和睫状肌麻痹。在过去的 2 年中,托吡卡胺在俄罗斯和意大利都有报道被用于静脉内(IV)自我给药,用于娱乐目的。
在 PsycInfo 和 Pubmed 数据库中搜索托吡卡胺的文献。考虑到缺乏同行评议的数据,结果与一系列网站、毒品论坛和其他在线资源(即电子新闻组、聊天室、邮件列表、电子新闻通讯和公告板)的多语言定性评估相结合:2012 年 1 月至 2013 年 1 月期间,使用通用和特定关键字(如“合法快感”、“研究化学品”、“在线药房”、“托吡卡胺”、“mydriacil”、“tropicacyl”、“visumidriatic”、“在线药房”和“托吡卡胺娱乐性滥用”)在谷歌搜索引擎中以英语和意大利语对 100 多个网站进行了探索性定性搜索。
托吡卡胺的滥用通常通过 IV 注射进行;其效果持续 30 分钟至 6 小时,通常与其他精神活性化合物一起服用,最常见的是酒精、大麻和阿片类药物。托吡卡胺滥用的医疗影响包括言语不清、持续散瞳、意识丧失/无反应、幻觉、肾痛、烦躁不安、“睁眼梦”、发热、震颤、自杀感、抽搐、精神运动兴奋、心动过速和头痛。
讨论/结论:需要进行更多的大规模研究来确认和更好地描述托吡卡胺在欧盟和其他地区滥用的程度。卫生和其他专业人员应迅速了解这种新的、令人警醒的滥用趋势。